insulin secretagogues peptides (incretins)

systematic review meta-analysis network meta-analysis

Select diabetes type 2 All type of patient       albiglutideglucagon-like peptide 1 receptor agonistglucagon-like peptide analogslixisenatide albiglutideexenatideliraglutidelixisenatide taspoglutide vs add on insulinvs add on oral therapyvs placebovs placebo or controlvs glitazonevs insulinvs oral therapy      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	cardiovascular events (32)All cause death (31)vomiting (28)A CHANGER (27)diarrhoea (26)severe hypoglycemia (25)HbA1c (22)Cardiovascular death (13)all hypoglycemia (12)serious adverse events (8)treatment-emergent adverse events (TEAEs) (7)severe adverse events (5)change in HbA1c (%) (3)change in body weight (kg) (1)change in daily mean glucose, mmol/L (1)change in FSG, mmol/L (1)myocardial infarction (fatal and non fatal) (1)stroke (fatal and non fatal) (1)retinopathy (1)nephropathy (1)microvascular events (1)hospitalisation for heart failure (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	cardiovascular events	All cause death
diabetes type 2
albiglutide
Seino, 2009      NCT	albiglutide	placebo			Exploratory	negative
Rosenstock (30 mg every two weeks), 2009      NCT	albiglutide biweekly	placebo (add on MET)			Low risk of bias	suggesting
Rosenstock (30 mg weekly), 2009      NCT	albiglutide weekly	placebo (add on MET)			Exploratory	suggesting
exenatide
NCT00360334    NCT	exenatide	glargine				negative
Derosa, 2010	exenatide 20µg	glibenclamide				negative
Liutkus, 2010	exenatide	placebo				negative
H8O-MC-GWBJ, 9698, 10µg/d, 2008	exenatide 10µg/d	placebo			Low risk of bias	-
Apovian, 2010	exenatide 20µg/d	placebo			Low risk of bias	negative
H8O-MC-GWBJ, 9698, 20µg/d, 2008	exenatide 20µg/d	placebo			Low risk of bias	-
Poon, 2005        NCT	exenatide other doses	placebo			Low risk of bias	-
NCT00085969    NCT	exenatide other doses	placebo			Low risk of bias	-
Moretto (DOUBLONS avec druker), 2008      NCT	exenatide other doses	placebo			Low risk of bias	negative
Buse, 2011      NCT	exenatide 20µg/d	placebo (add on insulin)			Low risk of bias	negative
Fineman, 2003	exenatide other doses	placebo (add on MER+/-SU)			Exploratory	-
DeFronzo 10µg/d, 2005          NCT	exenatide 10µg/d	placebo (add on MET)			Low risk of bias	negative
DeFronzo 20µg/d, 2005      NCT	exenatide 20µg/d	placebo (add on MET)			Low risk of bias	suggesting
Kim, 2007      NCT	exenatide weekly	placebo (add on MET)			Exploratory	negative
Gao, 2009      NCT	exenatide 20µg/d	placebo (add on MET+/-SU)			Low risk of bias	suggesting
Buse 10µg/d, 2004          NCT	exenatide 10µg/d	placebo (add on SU)				negative
Buse 20µg/d, 2004	exenatide 20µg/d	placebo (add on SU)				-
Kadowaki (trial 8683), 2009	exenatide 10µg/d	placebo (add on SU+/-MET/TZD)			Exploratory	negative
Kendall 10µg/d, 2005      NCT	exenatide 10µg/d	placebo (add on SU+MET)			Low risk of bias	negative
Kendall 20µg/d, 2005      NCT	exenatide 20µg/d	placebo (add on SU+MET)			Low risk of bias	suggesting
Zinman 20µg/j, 2007    NCT	exenatide 20µg/d	placebo (add on TZD+/-MET)			Low risk of bias	suggesting
Zinman 20µg/j A MODIFIER, 2007	exenatide 20µg/d	placebo (add on TZD+/-MET)			Low risk of bias	-
Gill, 2010	exenatide 10µg/d	placebo add on MET+/-TZD			Low risk of bias	negative
phase 2 exenatide once monthly	exenatide once monthly	weekly exenatide				-
Bergenstal (once daily), 2009	exenatide 20µg/d	BIAsp 30 daily			Risk of bias	-
Bergenstal (twice daily), 2009	exenatide 20µg/d	BIAsp 30 twice daily			Risk of bias	negative
Exenatide Trial 10749	exenatide before lunch and dinner	exenatide before breakfast and dinner			Risk of bias	-
HEELA (Davies), 2009	exenatide other doses	glargine				-
Heine, 2005	exenatide 20µg/d	insulin (add on SU+MET)				negative
Barnett, 2007      NCT	exenatide 20µg/d	insulin (add on SU/MET)			Exploratory	suggesting
Davis, 2007      NCT	exenatide 20µg/d	insulin (add on SU/MET)			Risk of bias	negative
Nauck, 2007      NCT	exenatide 20µg/d	insulin BIAsp twice daily add on SU+MET			Risk of bias	negative
DURATION-3 (Diamant), 2010    NCT	exenatide weekly	insulin glargine			Risk of bias	suggesting
Bunck, 2009          NCT	exenatide 20µg/d	insulin glargine (add on MET)			Exploratory	-
Trial 8078	exenatide other doses	insulin glargine (add on MET/SU)				-
LEAD 6 (Buse) exe vs lira, 2009	exenatide 10µg twice daily	liraglutide 1.8mg				-
DURATION-2 (Bergenstal) (vs pioglitazone), 2010      NCT	exenatide weekly	pioglitazone			Low risk of bias	suggesting
DeFronzo (EXE vs ROSI), 2010	exenatide 20µg/d	rosiglitazone add on MET			Exploratory	negative
DURATION-2 (Bergenstal) (vs sitagliptin), 2010      NCT	exenatide weekly	sitagliptin			Low risk of bias	suggesting
DeFronzo, 2008      NCT	exenatide 20µg/d	sitagliptin (add on MET)			Low risk of bias	-
Drucker, 2008      NCT	exenatide 20µg/d	weekly exenatide				-
liraglutide
NN2211-1333	liraglutide other doses					-
Pratley (1.8 vs 1.2), 2010	liraglutide 1.8mg	liraglutide 1.2mg				negative
LEADER, 2016      NCT	liraglutide	placebo			Low risk of bias	conclusive
Harder, 2004	liraglutide other doses	placebo			Exploratory	-
NN2211-1571 (Vilsbøll), 2007        NCT	liraglutide other doses	placebo			Exploratory	negative
Madsbad (vs placebo), 2004	liraglutide other doses	placebo				negative
Kaku 0.6mg, 2010	liraglutide other doses	placebo			Low risk of bias	suggesting
Seino, 2008      NCT	liraglutide other doses	placebo			Exploratory	negative
LEAD-2 (Nauck) (1.2mg vs placebo), 2009        NCT	liraglutide 1.2mg	placebo (add on MET)			Low risk of bias	suggesting
LEAD-2 (Nauck) (1.8mg vs placebo), 2009      NCT	liraglutide 1.8mg	placebo (add on MET)			Low risk of bias	suggesting
NN2211-1796      NCT	liraglutide other doses	placebo (add on MET)				-
LEAD-1 SU (1.2 mg vs placebo), 2009        NCT	liraglutide 1.2mg	placebo (add on SU)			Low risk of bias	suggesting
LEAD-1 SU (1.8 mg vs placebo), 2009      NCT	liraglutide 1.8mg	placebo (add on SU)			Low risk of bias	suggesting
LEAD-5 (vs placebo), 2009      NCT	liraglutide 1.8mg	placebo (add on SU+MET)			Low risk of bias	suggesting
LEAD-4 (1.2mg), 2009      NCT	liraglutide 1.2mg	placebo (add on TZD+MET)			Low risk of bias	suggesting
LEAD-4 (1.8mg), 2009      NCT	liraglutide 1.8mg	placebo (add on TZD+MET)			Low risk of bias	suggesting
Kaku 0.9mg, 2010	liraglutide other doses	placebo (on top SU)			Low risk of bias	suggesting
LEAD-6, 2009        NCT	liraglutide 1.8mg	exenatide on top MET/SU/MET+SU			Risk of bias	suggesting
Seino, 2010      NCT	liraglutide other doses	glibenclamide			Low risk of bias	negative
LEAD-3 mono 1.2mg (Garber), 2009          NCT	liraglutide 1.2mg	glimepiride			Low risk of bias	negative
LEAD-3 mono 1.8mg (Garber), 2009      NCT	liraglutide 1.8mg	glimepiride			Low risk of bias	negative
Madsbad (vs Glimepiride), 2004	liraglutide other doses	glimepiride			Exploratory	suggesting
LEAD-2 (Nauck) (1.2 mg vs glimepiride), 2009        NCT	liraglutide 1.2mg	glimepiride (add on MET)			Low risk of bias	negative
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009      NCT	liraglutide 1.8mg	glimepiride (add on MET)			Low risk of bias	negative
LEAD-5 (vs Glargine), 2009    NCT	liraglutide 1.8mg	insulin glargine (add on SU+MET)			Risk of bias	negative
LEAD 2 (1.8 vs 1.2), 2009	liraglutide 1.8mg	liraglutide 1.2mg				negative
LEAD 4 (1.8 vs 1.2), 2009	liraglutide 1.8mg	liraglutide 1.2mg				negative
LEAD 1 (1.8 vs 1.2), 2009	liraglutide 1.8mg	liraglutide 1.2mg				negative
Feinglos, 2005	liraglutide other doses	metformin			Exploratory	negative
LEAD-1 SU (1.2 vs rosiglitazone), 2009	liraglutide 1.2mg	rosiflitazone				suggesting
LEAD-1 SU (1.8 vs rosiglitazone), 2009      NCT	liraglutide other doses	rosiglitazone (add on SU)			Low risk of bias	suggesting
Pratley 1.2mg, 2010      NCT	liraglutide 1.2mg	sitagliptin			Risk of bias	suggesting
Pratley 1.8mg, 2010    NCT	liraglutide 1.8mg	sitagliptin			Low risk of bias	suggesting
lixisenatide
GETGOAL-L    NCT	lixisenatide	placebo (add on basal insulin)			Low risk of bias	-
Ratner DRI6012, 2010      NCT	lixisenatide	placebo (add on MET)			Exploratory	-
taspoglutide
Nauck 10 once weekly vs PBO, 2009      NCT	taspoglutide 10mg once weekly	placebo			Exploratory	suggesting
Nauck 20 every 2 weeks vs PBO, 2009	taspoglutide 20mg once every 2 weeks	placebo				suggesting
Nauck 20 once weekly vs PBO, 2009	taspoglutide 20mg once weekly	placebo				suggesting
Ratner (20mg once weekly), 2010      NCT	taspoglutide	placebo (add on MET)			Exploratory	suggesting